Canaccord Genuity Comments on Recent Journal Manuscripts Related to Thoratec Corporation's HeartMate II Device

In a report published Friday, Canaccord Genuity analyst Jason R. Mills reiterated a Buy rating and $45.00 price target on Thoratec Corporation (NASDAQ: THOR ). In the report, Canaccord Genuity noted, “The New England Journal of Medicine (NEJM) and Journal of Heart & Lung Transplantation (JHLT) both published manuscripts online